Suven Life Sciences Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant, an α4β2 Antagonist representing a Novel Mechanism of Action for the treatment of Major Depressive Disorder".
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial of Ropanicant (SUVN-911), a novel oral α4β2 nicotinic receptor antagonist being developed to treat Major Depressive Disorder (MDD). The trial is a randomized, double-blind, placebo-controlled study enrolling around 195 patients across 35 sites in the USA, with a 6-week treatment duration, conducted under a US FDA IND. The Phase-2b trial builds on positive Phase-2a results that showed meaningful improvement in depression symptoms and a favorable safety profile. Topline data is expected in the second half of 2026.
This is a clinical development milestone, not a commercial or revenue event, so near-term stock impact is likely limited. However, successful Phase-2b data in H2 2026 could be a significant value-creating catalyst for shareholders given the large unmet need in depression treatment.